Leflunomide

Leflunomide is a disease-modifying antirheumatic drug (DMARD) widely prescribed for the long-term management of rheumatoid arthritis and certain inflammatory joint disorders. Unlike simple pain relievers that only reduce symptoms temporarily, leflunomide works at the immune system level to slow the underlying disease process that leads to joint damage. This makes it an important therapy in patients where controlling disease progression and preserving joint function are key treatment goals.

The medicine functions by inhibiting pyrimidine synthesis in rapidly dividing immune cells, particularly activated lymphocytes that drive autoimmune inflammation. By reducing this abnormal immune activity, leflunomide helps decrease joint swelling, morning stiffness, pain, and progressive structural damage. Over time, many patients experience improved physical function and reduced flare frequency when the medication is taken consistently under medical supervision.

Leflunomide is typically introduced when patients have moderate to severe rheumatoid arthritis or when other first-line DMARDs are not adequately effective. Because it is a systemic immunomodulatory drug, careful monitoring is important during therapy. Liver function tests, blood counts, and blood pressure are usually checked periodically to ensure safe long-term use. When appropriately prescribed and monitored, leflunomide can play a significant role in comprehensive rheumatoid arthritis management.

Patients are generally advised to take the medicine regularly as directed and to report symptoms such as persistent nausea, unusual fatigue, or signs of infection. Leflunomide is contraindicated during pregnancy due to potential fetal risk, and proper medical guidance is essential before starting or stopping therapy. With proper selection and monitoring, it remains a valuable option for slowing inflammatory joint disease progression and maintaining long-term joint health.